Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug Development (2021)
Sequence: LLIILRRRIRKQAHAHSK
antisense oligonucleotides (ASOs; chimeric)
| Experiment Id | EXP002018 |
|---|---|
| Paper | Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug Development |
| Peptide | pVEC |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 1000 nM ASO1–pVEC + 1000 nM ASO2–pVEC (combined treatment) |
| Rna Concentration | 1000 nM ASO1 + 1000 nM ASO2 (each conjugated to pVEC) |
| Mixing Ratio | 1:1 (ASO1–pVEC : ASO2–pVEC) |
| Formulation Format | mixture of two CPP–ASO conjugates |
| Formulation Components | ASO1–pVEC + ASO2–pVEC |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro (bacterial culture) |
| Cell Lines Or Primary Cells | Staphylococcus aureus ATCC 25923 |
| Animal Model | |
| Administration Route | |
| Output Type | growth inhibition (agar plate / culture) |
| Output Value | Complete growth inhibition reported with 1000 nM + 1000 nM (ASO1+ASO2) |
| Output Units | |
| Output Notes | Petri dish agar assay: no S. aureus growth observed after combined ASO1–pVEC and ASO2–pVEC treatment. |
| Toxicity Notes | No standalone peptide toxicity noted; activity attributed to intact CPP–ASO conjugates. |
| Curation Notes |